(Q45083568)

9 December 2017

title

Enhancement of HIV DNA vaccine immunogenicity by the NKT cell ligand, alpha-galactosylceramide (English)

1 reference

9 December 2017

1 reference

11

1 reference

9 December 2017

Yaoxing Huang

1

1 reference

9 December 2017

Alex Chen

2

1 reference

9 December 2017

Xiangming Li

3

1 reference

9 December 2017

Zhiwei Chen

4

1 reference

9 December 2017

Wenyong Zhang

5

1 reference

9 December 2017

Yang Song

6

1 reference

9 December 2017

Deborah Gurner

7

1 reference

9 December 2017

David Gardiner

8

1 reference

9 December 2017

Sankha Basu

9

1 reference

9 December 2017

David D Ho

10

1 reference

9 December 2017

language of work or name

English

0 references

publication date

20 February 2008

1 reference

9 December 2017

1 reference

9 December 2017

volume

26

1 reference

9 December 2017

issue

15

1 reference

9 December 2017

page(s)

1807-1816

1 reference

Induction of immune responses by DNA vaccines in large animals

9 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.002

DNA vaccines: immunology, application, and optimization*

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.002

Approaches to enhance the efficacy of DNA vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.002

Augmentation of immune responses to HIV-1 and simian immunodeficiency virus DNA vaccines by IL-2/Ig plasmid administration in rhesus monkeys

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.002

Effective mucosal immunity to anthrax: neutralizing antibodies and Th cell responses following nasal immunization with protective antigen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.002

Inclusion of CpG adjuvant with plasmid DNA coding for NcGRA7 improves protection against congenital neosporosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.002

Regulation of CpG-induced immune activation by suppressive oligodeoxynucleotides

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.002

Cytokine-facilitated priming of CD8+ T cell responses by DNA vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.002

Human immunodeficiency virus type 2 DNA vaccine provides partial protection from acute baboon infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.002

Activation of natural killer T cells by alpha-galactosylceramide impairs DNA vaccine-induced protective immunity against Trypanosoma cruzi

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.002

Effects of antigen and genetic adjuvants on immune responses to human immunodeficiency virus DNA vaccines in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.002

Mouse CD1-specific NK1 T cells: development, specificity, and function

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.002

Recognition and function of Valpha14 NKT cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.002

Requirements for CD1d recognition by human invariant Valpha24+ CD4-CD8- T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.002

Glycolipids and phospholipids as natural CD1d-binding NKT cell ligands

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.002

Natural killer T cell ligand alpha-galactosylceramide enhances protective immunity induced by malaria vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.002

Immunization with alpha-galactosylceramide polarizes CD1-reactive NK T cells towards Th2 cytokine synthesis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.002

Inhibition of T helper cell type 2 cell differentiation and immunoglobulin E response by ligand-activated Valpha14 natural killer T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.002

Selective bystander proliferation of memory CD4+ and CD8+ T cells upon NK T or T cell activation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.002

Selective induction of NK cell proliferation and cytotoxicity by activated NKT cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.002

Activation of natural killer T cells by alpha-galactosylceramide rapidly induces the full maturation of dendritic cells in vivo and thereby acts as an adjuvant for combined CD4 and CD8 T cell immunity to a coadministered protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.002

The natural killer T (NKT) cell ligand alpha-galactosylceramide demonstrates its immunopotentiating effect by inducing interleukin (IL)-12 production by dendritic cells and IL-12 receptor expression on NKT cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.002

alpha-galactosylceramide induces early B-cell activation through IL-4 production by NKT cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.002

The interface between innate and acquired immunity: glycolipid antigen presentation by CD1d-expressing dendritic cells to NKT cells induces the differentiation of antigen-specific cytotoxic T lymphocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.002

SYFPEITHI: database for MHC ligands and peptide motifs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.002

Induction of AIDS virus-specific CTL activity in fresh, unstimulated peripheral blood lymphocytes from rhesus macaques vaccinated with a DNA prime/modified vaccinia virus Ankara boost regimen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.002

Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.002

Induction of potent immune responses by cationic microparticles with adsorbed human immunodeficiency virus DNA vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.002

Increased DNA vaccine delivery and immunogenicity by electroporation in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.002

Enhancing B- and T-cell immune response to a hepatitis C virus E2 DNA vaccine by intramuscular electrical gene transfer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.002

Recent advances in the discovery and delivery of vaccine adjuvants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.002

Glycolipid antigen induces long-term natural killer T cell anergy in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.002

The response of natural killer T cells to glycolipid antigens is characterized by surface receptor down-modulation and expansion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.002

Correlates of immune protection in HIV-1 infection: what we know, what we don't know, what we should know

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.02.002

10.1016/J.VACCINE.2008.02.002

7 January 2021

Identifiers

DOI

1 reference

9 December 2017

1 reference